Jazz Pharmaceuticals plc JAZZ

NAS: JAZZ | ISIN: IE00B4Q5ZN47   14/10/2025
133,81 USD (-0,98%)
(-0,98%)   14/10/2025
Grafiek Jazz Pharmaceuticals plc Grafiek Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc in het nieuws

3 oktober 2025 · FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer · Persbericht

22 september 2025 · Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses · Persbericht

9 september 2025 · Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma · Persbericht

21 augustus 2025 · Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference · Persbericht

20 augustus 2025 · Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025 · Persbericht

20 augustus 2025 · Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 · Persbericht

6 augustus 2025 · Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma · Persbericht

5 augustus 2025 · Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance · Persbericht

22 juli 2025 · Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 · Persbericht

10 juli 2025 · Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer · Persbericht

Profiel Jazz Pharmaceuticals plc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Mijn selecties